Back to search results

Investigating CardiAQ MCG for Acute Coronary Syndrome

This study is looking at how well a device called CardiAQ MCG can help doctors understand heart problems like ischemia (when your heart muscle doesn't get enough blood) and heart attacks. Researchers will use the CardiAQ MCG device to measure your heart's magnetic fields. They want to see if these measurements match up with what doctors find during a procedure called an angiography, which looks at your blood vessels. You might be able to join if you are 18 or older, of any gender, and are scheduled for an angiography or a procedure to improve blood flow to your heart. The main goal is to see the relationship between the CardiAQ MCG results and angiography findings, with data collected within 24 hours of each other. The current recruitment status is unclear.

Study design
This is an observational pilot study aiming to enroll 150 participants. It is not specified if it is randomized or blinded.
What's involved
You would need to consent before your planned heart procedure to allow time for study activities. Data will be taken within 24 hours of your angiography.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06481943

A Prospective Research Investigation of Ischemia Using MCG

Recruiting
Not specifiedAges 18+Observational
SB Technology, Inc.
~335 participants
Updated 2026-09-04 on ClinicalTrials.gov
What's tested:Sponsor MCG device (CardiAQ)

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relationship between pre-procedural MCG and the peri-procedural angiography-based measures
Measured over Data taken within 24 hours of each other

Conditions

Acute Coronary Syndrome

Explore related trials

Acute Coronary Syndrome

NCT06481943

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic

    Rochester, Minnesotastudy coordinator listed

    Recruiting

  • Mount Sinai Hospital

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kit Yee Au-Yeung, PhD · STUDY_DIRECTOR · SB Technology, Inc.

Who to contact

Maggie LeDang
[email protected]
408-981-8754
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Scheduled to undergo a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute myocardial infarction
Ability for participant to comply with study requirements
Patient consented before the planned, clinically indicated cath-lab procedure begins to allow sufficient time for study related activities
Written informed consent

Exclusion

Present STEMI
Pregnant or breastfeeding
Having an active atrial fibrillation episode as seen on most current 12-lead ECG
Active thoracic metal implant
Poor access to follow-up

What this trial measures

  • Relationship between pre-procedural MCG and the peri-procedural angiography-based measuresData taken within 24 hours of each other

    Utilize linear regression and logistic regression to determine whether a set of a priori MCG-based biomarkers can prospectively predict the objective clinical assessment of ACS, while statistically adjusting for covariates.